COLONY STIMULATING FACTOR 1 REGULATION AND ROLE IN BONE
COLONY STIMULATING FACTOR 1 REGULATION AND ROLE IN BONE
批准号:
6350661
负责人:
KARL Leonard INSOGNA
金额:
$23.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-02-01 至 2003-01-31
关键词:
DNA footprinting biological signal transduction colony stimulating factor gel mobility shift assay gene expression genetically modified animals growth factor receptors hematopoietic growth factor hormone regulation /control mechanism immunoprecipitation in situ hybridization interleukin 1 laboratory mouse northern blottings nuclear factor kappa beta osteoblasts osteoclast activating factor osteoclasts parathyroid hormones phosphorylation physiologic bone resorption polymerase chain reaction site directed mutagenesis tissue /cell culture tumor necrosis factor alpha western blottings
中文摘要
成骨细胞介导破骨的确切机制
英文摘要
The precise mechanism whereby osteoblasts mediate osteoclastic bone
resorption is unclear. One widely-held hypothesis is that activated
osteoblasts secrete cytokines that directly or indirectly influence
osteoclast formation or function. Although the nature of these putative
cytokines is unknown, compelling in vivo and in vitro data have emerged
to support a role for colony-stimulating factor-1 (CSF-1) as an
osteoblast-derived factor involved in osteoclast formation. Thus, in
vivo, deficiency of CSF-1 in the op/op osteopetrotic mouse causes a
failure of osteoclast formation and bone resorption while in vitro
studies have demonstrated that CSF-1 is critical for the proliferation
and differentiation of osteoclast progenitors, that CSF-1 stimulates
bone resorption in the fetal mouse metacarpal assay, and that CSF-1
receptors are present on osteoclasts. CSF-1 is synthesized as a soluble
or cell surface protein, and while we know that osteoblasts synthesize
both forms of CSF-1 I constitutively and in response to osteotropic
agents, little is known of their physiologic significance in bone
remodeling. Additionally, while we know that two key osteotropic agents,
parathyroid hormone (PTH) and tumor necrosis factor (TNF) increase
expression of the CSF-1 gene in osteoblasts, the precise mechanism by
which they do so is unclear. Finally, the precise physiologic role of
CSF-1 in bone remodeling in vivo is unknown. The long term goals of this
proposal are therefore: 1. to define the physiologic roles of the cell-
surface and soluble forms of CSF-1 in bone, by examining the effects of
cell-surface CSF-1 on osteoclast signaling in vitro, and by generating
two lines of genetically-altered mice that are each deficient in one of
the CSF-1 I isoforms; 2. to characterize the cellular mechanisms by
which TNF and PTH increase CSF-1 transcription in osteoblasts by
characterizing the NF-kappaB proteins that mediate TNF-induced CSF-1
gene expression and by identifying and characterizing the CSF-1 promoter
elements by which PTH mediates this response; and 3. to analyze the
role of CSF-1 in bone remodeling in vivo by characterizing in vivo and
in vitro a transgenic mouse model with targeted overexpression of CSF-1
in osteoblasts.
These studies will help to elucidate the regulation and role of a
cytokine which is critical in osteoclast development, and will improve
our understanding of the mechanisms of physiologic bone resorption, and
that induced by osteotropic agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
-
批准号:10585240
-
项目类别:
-
资助金额:$65.93万
-
财政年份:2023
-
负责人:KARL Leonard INSOGNA
-
依托单位:
An ounce of prevention: stopping menopausal bone loss before it starts
-
批准号:10324591
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2021
-
负责人:KARL Leonard INSOGNA
-
依托单位:
The Role of Sphingosine Kinases in Bone Anabolism
-
批准号:9274156
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2016
-
负责人:KARL Leonard INSOGNA
-
依托单位:
A novel SATB2 mutation illuminates bone anabolism
-
批准号:8874913
-
项目类别:
-
资助金额:$18.32万
-
财政年份:2014
-
负责人:KARL Leonard INSOGNA
-
依托单位:
A novel SATB2 mutation illuminates bone anabolism
-
批准号:8758799
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2014
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Calcitonin for Treating X-linked Hypophosphatemia
-
批准号:8319251
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2011
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Calcitonin for treating X-linked hypophosphatemia
-
批准号:8193343
-
项目类别:
-
资助金额:$22.35万
-
财政年份:2011
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Conditional Deletion of PTHrP in Articular Chondrocytes
-
批准号:7609121
-
项目类别:
-
资助金额:$4.86万
-
财政年份:2008
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Conditional Deletion of PTHrP in Articular Chondrocytes
-
批准号:7509044
-
项目类别:
-
资助金额:$4.86万
-
财政年份:2007
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Microcomputed tomography device (Scanco microCT35)
-
批准号:7389328
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2007
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
-
批准号:7194429
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2006
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
-
批准号:7294307
-
项目类别:
-
资助金额:$45.33万
-
财政年份:2006
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
-
批准号:7485048
-
项目类别:
-
资助金额:$44.56万
-
财政年份:2006
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
-
批准号:7673792
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2006
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
-
批准号:8104662
-
项目类别:
-
资助金额:$42.44万
-
财政年份:2006
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Core A: Administrative Core, PI., Karl Insogna
-
批准号:6774667
-
项目类别:
-
资助金额:$12.32万
-
财政年份:2004
-
负责人:KARL Leonard INSOGNA
-
依托单位:
EVALUATION OF DISORDERS OF CALCIUM METABOLISM
-
批准号:7206865
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2003
-
负责人:KARL Leonard INSOGNA
-
依托单位:
Soy Protein and Calcium Metabolism
-
批准号:7041626
-
项目类别:
-
资助金额:$1.42万
-
财政年份:2003
-
负责人:KARL Leonard INSOGNA
-
依托单位:
IMPACT ON DIETARY PROTEIN ON BONE-TURNOVER
-
批准号:7206896
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:KARL Leonard INSOGNA
-
依托单位:
LONG TERM IMPACT OF PROTEIN ON CALCIUM KINETICS
-
批准号:7206920
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2003
-
负责人:KARL Leonard INSOGNA
-
依托单位:
海外基金